Number of ordinary shares: 361,999,722
Countries of listing: US
Country of incorporation and main country of operation
Biodexa Pharmaceuticals PLC is incorporated in England and Wales. Its main country of operation is in the UK.
Proposed New Articles of Association (pdf)
Articles of Association (pdf)
Midatech Pharma Limited – Incorporation Documents (pdf)
Midatech Pharma PLC – Certificate of Re-registration (pdf)
Change of Name Biodexa Pharmaceuticals PLC (pdf)
Securities in issue
Details of the number of shares in issue are available here.
QCA Corporate Governance Code
Biodexa Pharmaceuticals has chosen to adopt the principles of the Quoted Companies Alliance Corporate Governance Code (the “QCA Code”). The QCA Code identifies ten principles to be followed in order for companies to deliver growth in long term shareholder value, encompassing and efficient, effective and dynamic management framework accompanied by good communication to promote confidence and trust.
The sections below set out the ways in which the Group applies the ten principles of the QCA Code in support of the Group’s medium to long-term success and identified areas where Biodexa Pharmaceuticals departs from the QCA Code recommendations, is available here.
This disclosure was last reviewed and updated on 28 March 2023.
Details of Biodexa Pharmaceuticals Board of Directors, including biographical information is available here.
The Board of Directors is responsible to the shareholders for the proper management of the Company. It intends to meet regularly to consider the strategy and direction of the Company, to review scientific, operational and financial performance and to advise on management appointments. All key operational and investment decisions are subject to Board approval. The Company Secretary is responsible for ensuring that the Board procedures are followed and applicable rules and regulations are complied with.
The Board has three Committees, Audit, Remuneration and Nominations.
The Audit Committee comprises Simon Turton (Chair), Sijmen de Vries and Stephen Parker, and will meet formally not less than twice every year and otherwise as required. The terms of reference of the Audit Committee can be found here.
The Remuneration Committee comprises Sijmen de Vries (Chair), Stephen Parker and Simon Turton and will meet not less than twice a year and at such other times as the chairman of the committee shall require. The terms of reference of the Remuneration Committee can be found here.
The Nominations Committee comprises the full Board and is chaired by Stephen Parker. The Nominations Committee will meet not less than once a year and at such other times as the chairman of the committee shall require. The terms of reference of the Nominations Committee can be found here.
Annual reports, interim reports and RNS
Copies of the Company’s annual reports and interim financial statements may be accessed here.
Circulars sent to shareholders are available here.
The City Code on Takeovers and Mergers published by the Panel on Takeovers and Mergers applies to the Company.
Details of the Company’s nominated adviser and other key advisers may be found here.
This information was last updated on 11 May 2023.
The Biodexa Pharmaceuticals team benefits from cross-functional expertise including formulation science and pharmaceutical development. With over 10 years’ experience of working together the team has translated multiple programmes from concept to clinic across three distinct technology platforms and apply extensive knowledge and expertise to deliver rapid R&D innovation and value creation.
CEO / CFO
Chief Scientific Officer
Group Financial Controller
VP Business Development
VP Head of Clinical Operations
Board of Directors
CEO / CFO
Senior Independent Non-executive Director
Sijmen de Vries
Annual General Meetings & Notices
Notice of 2023 AGM
Shareholder Circular and Notice of General Meeting to be held on 24 March 2023
Notice of General Meeting to be held on 16 October 2017